Published in Cancer Res on September 15, 2004
Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res (2009) 1.83
Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. PLoS One (2011) 1.51
Gene-environment interaction effects on the development of immune responses in the 1st year of life. Am J Hum Genet (2005) 1.19
RGS17, an overexpressed gene in human lung and prostate cancer, induces tumor cell proliferation through the cyclic AMP-PKA-CREB pathway. Cancer Res (2009) 1.07
Regulator of G protein signaling 6 mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species-dependent mechanism. Cancer Res (2011) 1.01
Regulator of G protein signaling 6 (RGS6) induces apoptosis via a mitochondrial-dependent pathway not involving its GTPase-activating protein activity. J Biol Chem (2010) 0.97
Expressional evaluation of vascular endothelial growth factor (VEGF) protein in urinary bladder carcinoma patients exposed to cigarette smoke. Int J Clin Exp Pathol (2012) 0.95
Cyclin D1 A870G polymorphism and the risk of colorectal cancer and adenoma. Br J Cancer (2006) 0.90
Molecular targeting of Gα and Gβγ subunits: a potential approach for cancer therapeutics. Trends Pharmacol Sci (2013) 0.87
RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated Dnmt1 degradation and promoting apoptosis. Oncogene (2013) 0.85
Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis (2010) 0.85
Regulator of G protein signaling 6 is a novel suppressor of breast tumor initiation and progression. Carcinogenesis (2013) 0.83
Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer. Cancer (2013) 0.79
Prediction of a time-to-event trait using genome wide SNP data. BMC Bioinformatics (2013) 0.79
RGS6 variants are associated with dietary fat intake in Hispanics: the IRAS Family Study. Obesity (Silver Spring) (2011) 0.78
A screening-testing approach for detecting gene-environment interactions using sequential penalized and unpenalized multiple logistic regression. Pac Symp Biocomput (2015) 0.78
Recrudescence mechanisms and gene expression profile of the reproductive tracts from chickens during the molting period. PLoS One (2013) 0.76
RGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer. AAPS J (2016) 0.76
Decreased RGS6 expression is associated with poor prognosis in pancreatic cancer patients. Int J Clin Exp Pathol (2014) 0.76
RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation. Oncotarget (2016) 0.75
The evolution of RGS proteins as drug targets - 20 years in the making. IUPHAR Review: "X". Br J Pharmacol (2017) 0.75
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet (2011) 9.49
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet (2008) 5.43
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
A risk model for prediction of lung cancer. J Natl Cancer Inst (2007) 4.25
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Laser-capture microdissection. Nat Protoc (2006) 3.80
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst (2008) 3.67
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
Proteomic applications for the early detection of cancer. Nat Rev Cancer (2003) 3.61
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
Global warming preceded by increasing carbon dioxide concentrations during the last deglaciation. Nature (2012) 3.17
The landscape of recombination in African Americans. Nature (2011) 3.06
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Stressing harms of physical inactivity to promote exercise. Lancet (2012) 2.93
Ice-shelf collapse from subsurface warming as a trigger for Heinrich events. Proc Natl Acad Sci U S A (2011) 2.83
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Focus on bladder cancer. Cancer Cell (2004) 2.59
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res (2008) 2.37
DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol (2011) 2.34
Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst (2008) 2.17
Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am J Epidemiol (2012) 2.16
Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst (2008) 2.15
Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov (2002) 2.15
Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) (2008) 2.11
Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res (2008) 2.11
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev (2003) 2.09
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res (2007) 2.07
An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila) (2008) 2.05
Dietary phytoestrogens and lung cancer risk. JAMA (2005) 2.04
Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res (2005) 1.98
Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst (2011) 1.97
An investigation into the human serum "interactome". Electrophoresis (2004) 1.93
Seasonal characteristics of the Indian Ocean Dipole during the Holocene epoch. Nature (2007) 1.92
A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics (2008) 1.88
Genetic modifiers of liver disease in cystic fibrosis. JAMA (2009) 1.88
Inherited variation at chromosome 12p13.33, including RAD52, influences the risk of squamous cell lung carcinoma. Cancer Discov (2011) 1.87
A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem (2007) 1.87
A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila) (2011) 1.86
What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer (2010) 1.86
2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics (2002) 1.85
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res (2007) 1.82
Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res (2010) 1.81
SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol (2004) 1.81
The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer (2006) 1.79
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet (2012) 1.77
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res (2012) 1.74
Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet (2013) 1.74
Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res (2003) 1.73
Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov (2007) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet (2004) 1.70
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol (2005) 1.69
Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin Chem (2003) 1.69
Re: short telomere length, cancer survival, and cancer risk in 47 102 individuals. J Natl Cancer Inst (2013) 1.69
Global climate evolution during the last deglaciation. Proc Natl Acad Sci U S A (2012) 1.67
Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics (2003) 1.66
Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol (2007) 1.65
Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res (2010) 1.65
Development and validation of a lung cancer risk prediction model for African-Americans. Cancer Prev Res (Phila) (2008) 1.63
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol (2013) 1.61
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol (2009) 1.61
Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett (2007) 1.58
Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res (2004) 1.57
Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol (2007) 1.55
Mediating effects of smoking and chronic obstructive pulmonary disease on the relation between the CHRNA5-A3 genetic locus and lung cancer risk. Cancer (2010) 1.55
Anoikis: cancer and the homeless cell. Nature (2004) 1.54
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology (2007) 1.54
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) (2011) 1.53
Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res (2002) 1.53
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res (2003) 1.51
Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. PLoS One (2011) 1.51
Counterpoint: The vision for a new diagnostic paradigm. Clin Chem (2003) 1.50
Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis (2010) 1.50
Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol (2002) 1.48
Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res (2010) 1.48
Joint association of genome-wide association study-identified susceptibility loci and dietary patterns in risk of renal cell carcinoma among non-Hispanic whites. Am J Epidemiol (2014) 1.46
Mapping the C. elegans noncoding transcriptome with a whole-genome tiling microarray. Genome Res (2007) 1.46
Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics (2008) 1.44
Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics (2003) 1.44
Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem (2005) 1.43
Laser capture microdissection technology. Expert Rev Mol Diagn (2007) 1.43